key: cord-1010814-higwff3u
authors: Benjamin, Laura A.; Paterson, Ross W.; Moll, Rachel; Pericleous, Charis; Brown, Rachel; Mehta, Puja R.; Athauda, Dilan; Ziff, Oliver J.; Heaney, Judith; Checkley, Anna M.; Houlihan, Catherine F.; Chou, Michael; Heslegrave, Amanda J.; Chandratheva, Arvind; Michael, Benedict D.; Blennow, Kaj; Vivekanandam, Vinojini; Foulkes, Alexander; Mummery, Catherine J.; Lunn, Michael P.; Keddie, Stephen; Spyer, Moira J.; Mckinnon, Tom; Hart, Melanie; Carletti, Francesco; Jäger, Hans Rolf; Manji, Hadi; Zandi, Michael S.; Werring, David J.; Nastouli, Eleni; Simister, Robert; Solomon, Tom; Zetterberg, Henrik; Schott, Jonathan M.; Cohen, Hannah; Efthymiou, Maria
title: Antiphospholipid antibodies and neurological manifestations in acute COVID-19: A single-centre cross-sectional study
date: 2021-08-12
journal: EClinicalMedicine
DOI: 10.1016/j.eclinm.2021.101070
sha: 9e1ac3985826dfaf28375e458644c694d29255cc
doc_id: 1010814
cord_uid: higwff3u

BACKGROUND: A high prevalence of antiphospholipid antibodies has been reported in case series of patients with neurological manifestations and COVID-19; however, the pathogenicity of antiphospholipid antibodies in COVID-19 neurology remains unclear. METHODS: This single-centre cross-sectional study included 106 adult patients: 30 hospitalised COVID-neurological cases, 47 non-neurological COVID-hospitalised controls, and 29 COVID-non-hospitalised controls, recruited between March and July 2020. We evaluated nine antiphospholipid antibodies: anticardiolipin antibodies [aCL] IgA, IgM, IgG; anti-beta-2 glycoprotein-1 [aβ(2)GPI] IgA, IgM, IgG; anti-phosphatidylserine/prothrombin [aPS/PT] IgM, IgG; and anti-domain I β(2)GPI (aD1β2GPI) IgG. FINDINGS: There was a high prevalence of antiphospholipid antibodies in the COVID-neurological (73.3%) and non-neurological COVID-hospitalised controls (76.6%) in contrast to the COVID-non-hospitalised controls (48.2%). aPS/PT IgG titres were significantly higher in the COVID-neurological group compared to both control groups (p < 0.001). Moderate-high titre of aPS/PT IgG was found in 2 out of 3 (67%) patients with acute disseminated encephalomyelitis [ADEM]. aPS/PT IgG titres negatively correlated with oxygen requirement (FiO(2)R=-0.15 p = 0.040) and was associated with venous thromboembolism (p = 0.043). In contrast, aCL IgA (p < 0.001) and IgG (p < 0.001) was associated with non-neurological COVID-hospitalised controls compared to the other groups and correlated positively with d-dimer and creatinine but negatively with FiO(2). INTERPRETATION: Our findings show that aPS/PT IgG is associated with COVID-19-associated ADEM. In contrast, aCL IgA and IgG are seen much more frequently in non-neurological hospitalised patients with COVID-19. Characterisation of antiphospholipid antibody persistence and potential longitudinal clinical impact are required to guide appropriate management.

The severe acute respiratory syndrome coronavirus 2 (SARSÀCoV-2), causing COVID-19 is not just a viral pulmonary infection with lifethreatening respiratory complications but a multiple-organ disorder accompanied by hypercoagulability [1] . Thromboembolic events involving arterial, venous and micro-circulation are commonly reported [2, 3] . While sepsis-induced hypercoagulability is a recognised complication of severe respiratory infections, most patients with COVID-19 maintain normal concentrations of coagulation factors, with normal prothrombin time, and other coagulation screening tests, and platelet counts, suggesting that COVID-19 induces a unique prothrombotic state [4] .

Antiphospholipid syndrome (APS) is an acquired autoimmune disorder with the potential for life-threatening complications [5] . Antiphospholipid antibodies (lupus anticoagulant [LA], IgG and/or IgM anti-beta-2 glycoprotein-1 [ab 2 GP1] and anticardiolipin antibodies [aCL] ) that persist for more than 12-weeks, are well-recognised causes of venous, arterial, microvascular thrombosis and/or pregnancy morbidity; cardinal features of APS [5] . These antiphospholipid antibodies, including those in criteria sets (LA, aCL and ab 2 GPI) as well as non-criteria sets (antibodies to Domain 1 of b 2 GPI ([ab 2 GPI-D1] and phosphatidylserine/ prothrombin antibodies [aPS/PT]), can activate the endothelium, platelets and neutrophils, thereby shifting the blood-endothelium interface to a prothrombotic state [6] . Initial reports have demonstrated an increased frequency of antiphospholipid antibodies in COVID-19 patients and evidence of thrombosis in vivo [7] . However, the interpretation of these results remains unsubstantiated as transient antiphospholipid antibodies can also occur during viral infections [8] .

The central nervous system is a major target of antiphospholipid antibodies [9] . Although thrombotic damage explains many of the neurological manifestations of APS, direct immune-mediated processes may also be involved [9] . The reason why patients develop different antiphospholipid antibody associated neurological symptoms is currently unknown. Possible explanations may relate to autoantibody classes or epitope targets. Neurological manifestations were reported in 36.4% of hospitalised COVID-19 patients in one study [10] . A limited number of case series have shown prevalent antiphospholipid antibodies in acute COVID-19 associated stroke [11À14] . However, these findings are only observational, and therefore, do not exclude the possibility that these prevalent antiphospholipid antibodies are incidental.

Catastrophic APS (CAPS) is a rare and severe form of APS, and associated with a high mortality rate [15] . The diagnostic criteria for CAPS include multiple organ failure developing over a short period, histopathological evidence of multiple small vessel occlusions and high titres of antiphospholipid antibodies [15] . In a CAPS registry, 56% of the reported cases developed neurological manifestations [16] , suggesting that this may be a common complication of APS.

The extent to which antiphospholipid antibodies contribute to thrombotic or immune-mediated neurological manifestations in COVID-19 is unclear. This study aimed to estimate the burden and determine the associations and clinical correlations of antiphospholipid antibodies in COVID-19 populations, with and without neurological manifestations.

We carried out a cross-sectional study of adult patients over 18 years of age who presented to University College London Hospital

Evidence before this study

We searched PubMed for articles published up to April 23rd, 2021, using the keywords "coronavirus", "COVID-19" and "antiphospholipid antibodies" "anticardiolipin", "beta-2 glycoprotein-I "phosphatidylserine/prothrombin", and "neurological manifestations", with no language restriction. The review indicated that neurological manifestations were an important complication of COVID-19. A limited number of case series showed elevated antiphospholipid antibodies amongst patients with neurological complications in COVID-19, but no study has determined any pathogenic associations.

Using nine antiphospholipid antibodies, we showed that antiphosphatidylserine/prothrombin (aPS/PT) IgG was associated with COVID-associated neurological manifestations, specifically acute disseminated encephalomyelitis (ADEM). This antiphospholipid antibody was related to venous thromboembolism, and severity of respiratory disease in the absence of systemic inflammation, suggestive of respiratory microvascular thrombosis. In contrast, anticardiolipin antibodies IgA and IgG were associated with non-neurological COVID-hospitalised controls, and correlated with hypercoagulability, respiratory and renal disease. Antiphospholipid antibodies are ubiquitous in COVID-19 and might have specific pathological roles in COVID-19 and neurological manifestations of COVID-19.

Our study provides the first biochemical evidence that implicates antiphospholipid antibodies in the neurological manifestations of COVID-19. Our preliminary findings show that aPS/PT IgG might be an important feature in COVID-19-associated ADEM, mediated by non-thrombotic mechanisms in the brain, but thrombotic mechanisms systemically. Characterisation of whether these antiphospholipid antibodies are persistent and their potential longitudinal clinical impact are required, in order to guide appropriate management.

between March and June 2020 and met the European Centre for Disease Prevention and Control (ECDC) definition of COVID-19 [17] . Participants with new neurological signs or symptoms according to standardised definitions within 40 days of respiratory or systemic COVID-19 symptoms were defined as having a COVID-neurological illness [18] . Participants meeting the ECDC definition of COVID-19 but without neurological signs/symptoms or history of significant neurological disease were defined as COVID-hospitalised controls; they were hospitalised during the same period as the neurological cases. Participants with positive SARS-CoV-2 PCR who did not require hospital admission and had serology samples collected contemporaneously in a previously described study, represented COVID-nonhospitalised controls [19] .

We further classified COVID-neurological cases as (1) 'central': encephalitis; encephalopathy; acute disseminated encephalomyelitis (ADEM) or stroke and other (including intracranial hypertension and a central pain syndrome); (2) 'peripheral': Guillain-Barr e syndrome (GBS) or (3) other according to clinical consensus criteria as previously described [12] .

Clinical data were extracted from electronic records (EPIC, Madison, WI, USA). Patient characteristics, including age, sex, ethnicity, major co-morbidities, laboratory studies, and treatments were recorded, as described previously [12] . Clinical outcomes, including venous thromboembolism outside the central nervous system, ITU admission and 28-day mortality, were determined based on the review of electronic notes in January 2021. Additional blood was collected alongside samples collected as part of standard clinical care with written informed consent. Consent was obtained according to the Declaration of Helsinki. The Queen Square ethics committee approved this study (12-LO-1540).

We evaluated nine different antiphospholipid antibodies following the national and international guidelines [5, 20, 21] using Quanta Lite aCL IgG, aCL IgM, aCL IgA, ab 2 GPI IgG, ab 2 GPI IgM, ab 2 GPI IgA, aPS/PT IgG, and aPS/PT IgM kits (Inova Diagnostics Inc.), according to the manufacturer's instructions [22] . Positivity for aCL was defined as greater than the 99th centile (>20 GPLU or MPLU), for ab 2 GPI as greater than the 99th centile (>20 SGu or SMu) and for aPS/PT as greater than the 99th centile (˃30 IgG or IgM units).

Antibodies against domain I B 2 GPI (aD1b 2 GPI) IgG were established as previously reported [23] . Purified aD1b 2 GPI isolated from a patient's serum with APS was used as the calibrator, serially diluted to obtain a standard curve and arbitrary activity units assigned to each point. aD1b 2 GPI activity was defined as DI units (GDIU) and calculated as per aCL and ab 2 GPI assays. aD1b 2 GPI positivity was defined as >99th percentile of the mean activity of 200 healthy individuals [23] . The cut-off that defined a moderate or high titre for aD1b 2 

Continuous variables were summarised using means and medians and compared using Student's independent-samples t-test or Mann-Whitney U test as appropriate. Assumption of normality was verified for the appropriate reporting of means. Furthermore, distributions were verified to be similar, for the assumptions of the Mann-Whitney U test to hold. Categorical data were presented as percentages and compared using a chi-squared test. Pearson's product-moment correlation analysed linear correlations between antiphospholipid antibodies and other markers. The strength and direction of relationships were measured using simple linear regression, examining residuals to ensure fulfilment of linear regression assumptions. All statistical analyses and graphs were generated using Stata 14 (College Station, TX, USA) and Prism 8.3.1 (GraphPad, La Jolla, California, USA); p < 0.05 was considered significant. We report medians and interquartile range(IQR).

The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. LAB, RP, and ME had full access to all data and the final responsibility to submit for publication.

One hundred and six adult participants (30 COVID-neurological cases, 47 non-neurological COVID-hospitalised controls, 29 COVIDnon-hospitalised controls) were included in this cross-sectional study. The median (IQR) age was 55-years (43, 62), of whom 39 (37%) were female. Demographic and clinical characteristics are presented in Table 1 . The COVID-non-hospitalised controls had only demographic and no detailed illness data. They were presumed to be healthy with mild COVID-19 illness, and therefore, did not necessitate hospital admission. Amongst all clinical characteristics of hospitalised individuals, only World Health Organisation (WHO) COVID-19 severity classification, low molecular weight heparin (LMWH) treatment status, ITU admission, and 28-day mortality differed significantly between the COVID-hospitalised controls and COVIDneurological cases. The COVID-hospitalised controls compared with the COVID-neurological group had a more (WHO) severe illness (87% versus 32%; p < 0.001), were more likely to be on treatment dose LMWH (35% versus 4%; p = 0.003), admitted to ITU (83% versus 24%; p =< 0.001) and die by 28-days (26% versus 7%; p = 0.042). When comparing the COVID-non-hospitalised with the hospitalised group, the non-hospitalised controls were younger (median 43-years [38,52]<0.001), less frequently male (<0.05) and more likely to be white in ethnicity (<0.05) ( Table 1) .

Seventy-two of the 106 patients (67.9%) tested positive for at least one type of antiphospholipid antibodies ( Table 2 ).

In the COVID-neurological cohort, 22 (73.3%) were positive for at least one antiphospholipid antibody; 10 (33%) for at least two antiphospholipid antibodies and 7 (23.3%) for three or more. ACL IgM exhibited the highest prevalence (56.7%) followed by aB 2 GPI IgA (26.7%), aPS/PT IgG and IgM and then aD1b 2 GPI IgG (10%). One neurological patient had an unexpectedly high level of aD1b 2 GPI IgG (>1000 units/ml) and this case is described in Supplement Table 1 . Notably, aPS/PT IgG antiphospholipid antibody had moderate-high titre levels only in the COVID-neurological group (Table 3) . Overall, a total of 16 (53.3%) were positive for at least one antiphospholipid antibody used in the APS criteria (aB 2 GPI and aCL IgG and IgM) and 9 (30%) for two (Table 2) . Furthermore, 11 (36.6%) COVID-neurological patients exhibited moderate (40 units) and 6 (20%) had high (80 units) titres.

Similarly, antiphospholipid antibodies were also common in the non-neurological COVID-hospitalised controls. Thirty six (76.6%) were positive for at least one antiphospholipid antibody, 22 (46.8%) positive for at least two antiphospholipid antibodies and 13 (27.7%) In contrast, the prevalence of antiphospholipid antibodies in the COVID-non-hospitalised participants was considerably lower; only 14 (24.1%) were positive for aCL IgM. aPS/PT IgM (20.7%) occurred more frequently in this group compared to the others. Only 14 (48.2%) of the patients were positive for at least one antiphospholipid antibody, and 4 (13.8%) were positive for two antiphospholipid antibodies and none were triple positive. Only 9 (31.0%) patients were positive for at least one antiphospholipid antibody from the APS criteria and none for two. Out of the 29 COVID-non-hospitalised patients only 7 (24.1%) had moderate titres and no patients had high titres.

To understand the relationship between antiphospholipid antibodies, COVID-neurological patients, non-neurological COVID-hospitalised and non-hospitalised controls, we investigated whether there were any associations between antiphospholipid antibody titres and the different groups. We found that COVID-neurological and COVID-hospitalised patients had significantly higher levels of aB 2 GPI IgA and IgG, aCL IgM, and aB 2 GPI-D1 IgG compared to the COVID-non-hospitalised group (p < 0.01 in all cases, Fig. 1 and Supplement Table 2 ). Of these antiphospholipid antibodies, we found that the median aCL IgM met the moderate-high cut-off in both hospitalised groups.

Despite COVID-hospitalised control patients exhibiting a more severe COVID-19 illness (Table 1) , there were no significant differences in titres between ab 2 GP1 IgA (p = 0.152) and IgG (p = 0.338), aCL IgM (p = 0.761) and aD1b 2 GPI IgG (p = 0.270) compared with the COVID-neurological group (Fig. 1) . However, aCL IgA (p = 0.001) and IgG (p = 0.020) titres were associated with COVID-hospitalised control group.

In contrast, in the COVID-neurological group aPS/PT IgG was significantly higher than both control groups (p < 0.01 in all cases, Fig. 1 and Supplement Table 2 ), indicating a degree of specificity for neurological disease. We explored the neurological subtype associated with elevated aPS/PT IgG; two cases out of three were above the moderate-high titre threshold, both with a diagnosis of acute disseminated encephalomyelitis (ADEM); case 218 is an example with accompanying histopathology (Fig. 2) .

Interestingly, aPS/PT IgM was associated with COVID-non-hospitalised controls compared to the other groups (p < 0.01), and aB 2 GPI IgM was non-discriminatory across all groups.

To consolidate our findings and gain further insight into the relationship between antiphospholipid antibodies and the COVID-neurological group, we combined all hospitalised groups to assess the potential correlation between antiphospholipid antibodies and clinical and laboratory markers of COVID-19 disease severity and outcome.

We found aPS/PT IgG titre correlated with FiO 2 (R=À0.15 p = 0.040) but not with CRP (R=À0.02, p = 0.549) or D-dimer (R = 0.11, 0.649) ( Table 4 ). In contrast, aCL IgG and IgA correlated with creatinine (aCL IgG, R = 0.32, p = 0.016; aCL IgA, R = 0.33, p = 0.005), FiO 2 and D-dimer (aCL IgG only; R0.25, p = 0.011). Additionally, FiO 2 was negatively correlated with aCL IgM (R=À0.25, p = 0.011), ab 2 GP1 IgM (R=À0.14, p = 0.040) and aD1b 2 GPI (R=À0.31, p = 0.041). Of these antiphospholipid antibodies, aCL IgM and aD1b 2 GPI IgG titres were significantly increased in both the COVID-neurological and hospitalised groups than the COVID-non-hospitalised controls (Supplement Table 2 ).

The association between antiphospholipid antibodies and outcome measures (28-day mortality, ITU admission, venous thromboembolism, and ischaemic arterial stroke) was also assessed. Of all the antiphospholipid antibodies, raised aPS/PT IgG titre was associated with venous thromboembolism (p = 0.043), and raised aCL IgA titre was associated with ITU admission (p = 0.021) (Supplement Table 3 ).

Increased aCL IgA (p = 0.020) and b 2 GP1 IgA (p = 0.046) was associated with not having an ischaemic stroke.

We report the first study to examine the prevalence and pattern of antiphospholipid antibodies and associations with the neurological manifestations of COVID-19 in comparison to hospitalised and nonhospitalised COVID-19 controls. We examined nine different antiphospholipid antibodies and showed high prevalence of antiphospholipid antibody in both the COVID-neurological and COVIDhospitalised controls as compared with the COVID-non-hospitalised controls. Importantly, we made the novel observation that raised aPS/PT IgG was associated with COVID-neurological manifestation, specifically ADEM. This antiphospholipid antibody was also related to venous thromboembolism, and respiratory disease (declining oxygen requirement) in the absence of systemic inflammation (CRP). In contrast, antibodies that distinguished COVID-hospitalised controls, including aCL IgA and IgG, were associated with hypercoagulability Table 3 Proportion of neurological patients with moderate-high antiphospholipid antibody titre in COVID-19. (elevated D-dimer), respiratory and renal disease (increasing creatinine), thereby exhibiting features of the thrombo-inflammatory complications seen in COVID-19 [1, 24] . Together, these results provide evidence that antiphospholipid antibodies are ubiquitous and might have a pathological role in COVID-19 and neurological manifestations of COVID-19. Antiphospholipid antibodies are a heterogeneous group of antibodies that are important in the pathogenesis of antiphospholipid syndrome, targeting various phospholipid-binding plasma proteins such as b 2 GPI and prothrombin that bind phospholipids such as cardiolipin [5] . Their association with infections, especially viral infections, is recognised [8] . While the detection of antiphospholipid antibodies in viral infection is usually incidental, some viruses, such as hepatitis C, generate antiphospholipid antibody that is associated with thrombosis [8] . The generation of antiphospholipid antibodies in SARS-CoV-2 could be explained by molecular mimicry and neoepitope formation of the phospholipid-like epitope, via the S protein on the viral cell wall, inducing the generation of antiphospholipid antibodies [25] . Antibodies generated against these phospholipid-like proteins of SARS-CoV-2 could trigger an immunogenic response if those proteins are shared with native tissues. Notably, the generation of IgG aPS/PT cross-reacting with myelin-related protein, specifically phosphatidylserine, which is abundantly found in myelin, could potentially give rise to ADEM [9, 26] . The histopathology of one of these ADEM cases demonstrated myelin-dependant pathobiology in the absence of cerebral thrombosis. In contrast, the correlation with declining oxygen requirement, trend with increasing hypercoagulability (increasing D-dimer) in the absence of systemic inflammation (CRP), is likely attributable to respiratory microvascular thrombosis [27] . The CT chest imaging of our ADEM case showed the characteristic bilateral ground-glass appearances recognised in COVID-19 [27] . Furthermore, the association with venous thromboembolism raises the possibility of co-existing thrombotic complications. Importantly, the risk of aPS/PT IgG persisting and developing antiphospholipid syndrome remains [9] . Longitudinal studies are needed, especially to ascertain clinical impact, in order to guide appropriate management. Catastrophic antiphospholipid syndrome (CAPS) involves derangements of both inflammatory and thrombotic pathways and affects multiple organs in the body simultaneously [15] . In the CAPS registry, the most frequently affected organs were the kidneys (73%), and the lungs (60%), and the presence of aCL IgG antibody (81%) was common [28] . In our non-neurological COVID-hospitalised controls, we not only showed a modestly high rate of aCL IgG (21%) but also, an association with multiple organ disease (respiratory, renal), and hypercoagulability (raised D-dimer). While these abnormally correlated biomarkers may point to possible CAPS in the COVID-hospitalised controls, we had less evidence for this in the COVID-neurological group, who, in general, had a less severe systemic COVID-19 illness.

Moderate-high titre thresholds for antiphospholipid antibodies were similar in both the COVID-neurological group (36.6% and 20%, respectively) and COVID-hospitalised controls (53% and 19.1%, respectively) compared to the COVID non-hospitalised controls, where only 24.1% had moderate titres. Furthermore, the COVID-neurological group had similar antibody titres to hospitalised controls for aB 2 GPI IgA and IgG, aCL IgM, and aB 2 GPI-D1 IgG. IgM aCL was noteworthy, given its high prevalence of moderate-high titre thresholds. Moreover, its correlation with hypercoagulability and respiratory disease inferred a pathogenic potential. Importantly, and consistent with other reports, we showed no association between aCL IgM and large-vessel thrombosis in the pulmonary veins, deep veins or cerebral arteries [7] .

The identification of a very high aD1b 2 GPI IgG (>1000unit/ml) titre is important. b 2 GPI is a crucial plasma protein in maintaining haemostasis, pathogenic antibodies to this target can result in a prothrombotic state [29] . Moreover, all domains of b 2 GPI have been described as targeted by antiphospholipid antibody, but the most clinically significant to date is antibodies to domain I [30] . The delayed presentation, in our case, is consistent with the recent description of a biphasic presentation of encephalopathy, with the delayed phase (approximately 20-days) reported as more severe [31] . The exact mechanism is unclear, and could be immune-mediated. However, the concurrent negative correlation with aD1b 2 GPI and declining oxygen requirement, raises the possibility of microvascular thrombosis in the respiratory system, which could also occur in the brain [27] . Our study has several limitations. Sample sizes were constrained by the number of cases with COVID-neurological manifestations identified during the first UK COVID-19 wave when mass hospitalisations occurred. However, in the context of this novel cohort, we identified preliminary target antiphospholipid antibodies associated with hospitalised COVID-19 and neurological manifestation of COVID-19. We did not screen for pre-morbid renal impairment, although we do not think it was prevalent, it could potentially have confounded the correlation analysis with antiphospholipid antibodies. Patients were tested for DVT or PE using doppler ultrasound and CT pulmonary angiogram respectively, if symptomatic or had persistently elevated D-dimer. There remains the possibililty of missing asymptomatic thromboembolism, but we think that this would have been in the minority. We did not have access to the required volume of citrated plasma samples needed for lupus anticoagulant testing. This would have provided additional context and risk stratification for the antiphospholipid antibody profiling results. However, we speculate that levels would have been comparable to aPS/PT as previously described [32] . For hospital-based studies, access to non-hospitalised controls is challenging. Although our non-hospitalised cohort was significantly younger and healthier, it provided a useful comparator group and the opportunity to encompass the full spectrum of COVID-19 disease severity. A non-COVID control group would have been useful to explore the relevance of antiphospholipid antibodies independently associated with mild COVID-19 disease such as aPS/PT IgM. We acknowledge that our sampling was opportunistic and not defined by a disease time point. However, we found no significant difference in the timing from COVID-19 onset to blood sampling between our hospitalised groups (data not shown). Furthermore, prophylactic or treatment dose anticoagulation was used as a prevention strategy, which could have confounded our findings. Future studies should endeavour to systematically track antiphospholipid antibodies over the full course of hospitalisation and at a 12-weeks interval, with a careful recording of drugs that interact with the clotting mechanisms.

In summary, we provide the first insight into the pathobiology of antiphospholipid antibodies in the neurological manifestation of COVID-19. We identified a high prevalence of antiphospholipid (arrow) . Initial axial T 2 (I and J) and T 2 *-weighted images (K) show multifocal confluent T 2 hyperintense lesions involving internal and external capsules, splenium of corpus callosum (I), and the juxtacortical and deep white matter (J), associated with microhaemorrhages (K, arrows). Follow-up T 2 -weighted images (M and N) show marked progression of the confluent T 2 hyperintense lesions, which involve a large proportion of the juxtacortical and deep white matter, corpus callosum and internal and external capsules. The followup SWI image (O) demonstrates not only the previously seen microhaemorrhages (arrows) but also prominent medullary veins (short arrows). CT pulmonary angiogram excluded a pulmonary embolism but showed mild patchy ground-glass changes peripherally at the lung bases bilaterally characteristic of COVID-19 (not shown). REPRODUCED FROM PATER-SON AND COLLEAGUES, BY PERMISSION OF OXFORD UNIVERSITY PRESS. antibodies in both hospitalised groups, and found that aPS/PT IgG might be an important factor in the manifestation of ADEM, mediated by non-thrombotic mechanisms in the brain and possibly associated with thrombotic complications systemically. In contrast, aCL IgA and IgG may have a pathological role in non-neurological hospitalised patients with COVID-19. Characterisation of whether these antiphospholipid antibodies are persistent and their potential longitudinal clinical impact are required to guide appropriate management.

LAB reports grants from GlaxoSmithKline, grants from Wellcome Trust, outside the submitted work.; RWP reports grants from Neurofilament light consortium, personal fees from GE healthcare educational talk, outside the submitted work.; CP is co-inventor for a patented Domain I-based potential therapeutic for APS.; KB reports personal fees from Abcam (advisory board / consultant), personal fees from Axon (advisory board / consultant), personal fees from Biogen (advisory board / consultant), personal fees from Julius Clinical (data monitoring committee), personal fees from Lilly (advisory board / consultant), personal fees from MagQu (advisory board / consultant), personal fees from Novartis (data monitoring committee), personal fees from Roche Diagnostic (advisory board / consultant), personal fees from Siemens Healthineers (advisory board / consultant), outside the submitted work; and is co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program.; CM reports personal fees from Biogen (sit on steering committee for aducanumab fees for time spent), personal fees from Roche (advisory board member fees for time spent), personal fees from Washington University (sit on therapeutic evalutation committee fees for time spent), outside the submitted work.;

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Coagulation abnormalities and thrombosis in patients with COVID-19

International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)

The pathogenesis of the antiphospholipid syndrome

Prothrombotic autoantibodies in serum from patients hospitalised with COVID-19

Risk of developing antiphospholipid antibodies following viral infection: a systematic review and meta-analysis

Antiphospholipid antibodies overlapping in isolated neurological syndrome and multiple sclerosis: neurobiological insights and diagnostic challenges

Neurologic manifestations of hospitalised patients with coronavirus disease 2019 in Wuhan, China

Characteristics of ischaemic stroke associated with COVID-19

The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings

COVID-19 and ischemic stroke: a systematic review and meta-summary of the literature

Cerebral venous thrombosis in patients with COVID-19 infection: a case series and systematic review

The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: a comprehensive review

Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of 500 patients from the International CAPS Registry

ECDC) ECfDPaC. Case definition for coronavirus disease 2019 (COVID-19), as of 3

Neurological associations of COVID-19

Pandemic peak SARS-CoV-2 infection and seroconversion rates in London frontline health-care workers

British Committee for standards in H. guidelines on the investigation and management of antiphospholipid syndrome

Subcommittee on Lupus anticoagulant/antiphospholipid antibody of the scientific and standardisation committee of the international society on thrombosis and haemostasis

Testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the ISTH

Measuring IgA anti-beta2-glycoprotein I and IgG/IgA anti-domain I antibodies adds value to current serological assays for the antiphospholipid syndrome

Thromboinflammation and the hypercoagulability of COVID-19

Origin of antiphospholipid antibodies: induction of aPL by viral peptides

Lipid autoreactivity in multiple sclerosis

Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working hypothesis

Anti-phospholipid syndrome and COVID-19 thrombosis: connecting the dots

The antiphospholipid syndrome

Proof-of-concept study demonstrating the pathogenicity of affinity-purified IgG antibodies directed to domain I of beta2-glycoprotein I in a mouse model of anti-phospholipid antibody-induced thrombosis

Spectrum, risk factors, and outcomes of neurological and psychiatric complications of COVID-19: a UK-wide cross-sectional surveillance study

Antiphosphatidylserine/prothrombin antibodies (aPS/PT) as potential diagnostic markers and risk predictors of venous thrombosis and obstetric complications in antiphospholipid syndrome

The authors would like to thanks Dr Thomas McDonnell who prepared aD1b 2 GPI ELISAs, and Prof Anisur Rahman for his supervision.

LB, RP, HC and ME devised the idea for this cross-sectional study. LB and ME contributed to the literature search. ME, CP, and RM performed the experiments. Statistical analysis was performed by LB and ME. LB, RP, CP, HC and ME prepared the initial manuscript draft. All authors contributed to, reviewed, and approved the final draft of the paper.

The authors declare that all supporting data are available within the article (and its online supplementary files). Any query should be submitted to the corresponding author.

Supplementary material associated with this article can be found in the online version at doi:10.1016/j.eclinm.2021.101070.